Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gentian Diagnostics ASOSL:GENT 77 Equity-to-Asset is 0.82 as of Jun. 2026, which is 4% below its 10-year median of 0.85. GuruFocus rates OSL:GENT with a GF Score™ of 77/100 and a GF Value™ of kr60.42 (Significantly Undervalued). Among 852 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks better than 79.11% on this metric.
The historical rank and industry rank for Gentian Diagnostics AS's Equity-to-Asset or its related term are showing as below:
OSL:GENT'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.79 Med: 0.85 Max: 0.97
Current: 0.82
During the past 13 years, the highest Equity to Asset Ratio of Gentian Diagnostics AS was 0.97. The lowest was 0.79. And the median was 0.85.
OSL:GENT's Equity-to-Asset is ranked better than 79.11% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs OSL:GENT: 0.82
Gentian Diagnostics AS (OSL:GENT) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Gentian Diagnostics AS Equity-to-Asset Related Terms
Gentian Diagnostics AS Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:GENT vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Equity-to-Asset falls into.
Gentian Diagnostics AS Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Gentian Diagnostics AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (OSL:GENT) has a Equity-to-Asset of 0.82 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Gentian Diagnostics AS and its competitors. This is near median its historical median of 0.85. Over the past decade, Gentian Diagnostics AS's Equity-to-Asset has ranged from 0.79 to 0.97. According to the industry distribution chart, Gentian Diagnostics AS ranks #178 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 20.9%.
Is Gentian Diagnostics AS's Equity-to-Asset too high?
Gentian Diagnostics AS's current Equity-to-Asset of 0.82 is near median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 0.97. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Gentian Diagnostics AS's value of 0.82 is 28.1% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #178 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gentian Diagnostics AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #178 out of 852 companies for Equity-to-Asset. This places Gentian Diagnostics AS in the top 21% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Gentian Diagnostics AS's value of 0.82 is 28.1% above this benchmark. Historically, Gentian Diagnostics AS's own Equity-to-Asset has ranged from 0.79 to 0.97 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.64, Gentian Diagnostics AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Equity-to-Asset of 0.82 is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Equity-to-Asset is 0.82, which is near median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr60.42, compared to a current price of kr39.40 — trading 34.8% below its estimated fair value. The current Equity-to-Asset is 0.82, which is near median its 10-year median of 0.85 and 28.1% above the Medical Devices & Instruments industry median of 0.64. Gentian Diagnostics AS's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Equity-to-Asset is 0.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr39.40 is trading 34.8% below its estimated GF Value™ of kr60.42.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
Equity-to-Asset: 0.82 (near median its 10-year median of 0.85)
GF Value™: kr60.42 vs. price of kr39.40 (34.8% below fair value)
Industry Position: 28.1% above the Medical Devices & Instruments median (#178 of 852)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
77GF Score
Get the complete analysis for OSL:GENT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
